Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q37463892)
Watch
English
Immunotherapy of metastatic renal cell carcinoma
scientific article published on May 2009
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
19402060
retrieved
20 August 2017
review article
1 reference
stated in
Europe PubMed Central
retracted paper
2 references
stated in
Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"
stated in
Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine
title
Immunotherapy of metastatic renal cell carcinoma
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
19402060
retrieved
20 August 2017
main subject
immunotherapy
1 reference
based on heuristic
inferred from title
author name string
David F McDermott
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
19402060
retrieved
20 August 2017
language of work or name
English
0 references
publication date
1 May 2009
1 reference
stated in
Europe PubMed Central
PubMed ID
19402060
retrieved
20 August 2017
published in
Cancer
1 reference
stated in
Europe PubMed Central
PubMed ID
19402060
retrieved
20 August 2017
volume
115
1 reference
stated in
Europe PubMed Central
PubMed ID
19402060
retrieved
20 August 2017
page(s)
2298-2305
1 reference
stated in
Europe PubMed Central
PubMed ID
19402060
retrieved
20 August 2017
issue
10 Suppl
1 reference
stated in
Europe PubMed Central
PubMed ID
19402060
retrieved
20 August 2017
cites work
Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Immunotherapy for metastatic renal cell carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of metastatic renal cell carcinoma with activated autologous macrophages and granulocyte--macrophage colony-stimulating factor
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcom
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sorafenib in advanced clear-cell renal-cell carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1002%2FCNCR.24236
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Immunotherapy for advanced renal cell cancer
1 reference
stated in
COCI
retrieved
30 December 2023
reference URL
https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD001425.PUB2
Interferon therapy for the treatment of renal cancer
1 reference
stated in
COCI
retrieved
30 December 2023
reference URL
https://opencitations.net/index/api/v1/references/10.1002/CNCR.24236
Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumors
1 reference
stated in
COCI
retrieved
30 December 2023
reference URL
https://opencitations.net/index/api/v1/references/10.1002/CNCR.24236
Identifiers
DOI
10.1002/CNCR.24236
1 reference
stated in
Europe PubMed Central
PubMed ID
19402060
retrieved
20 August 2017
PubMed ID
19402060
1 reference
stated in
Europe PubMed Central
PubMed ID
19402060
retrieved
20 August 2017
ResearchGate publication ID
24376925
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit